PubMed

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.

Diabetes Care. 2003 Mar;26(3):590-6.PMID: 12610006 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.

Diabetologia. 2004 Apr;47(4):622-9.PMID: 15298338 [PubMed - indexed for MEDLINE]Related articles

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

Standl E, Lang H, Roberts A.

Diabetes Technol Ther. 2004 Oct;6(5):579-88.PMID: 15628811 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

Diabetes Care. 2004 May;27(5):1081-7.PMID: 15111525 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.

Diabetes Care. 2001 Feb;24(2):296-301.PMID: 11213882 [PubMed - indexed for MEDLINE]Related articlesFree article

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.

Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.

Diabetes Obes Metab. 2005 Jan;7(1):56-64.PMID: 15642076 [PubMed - indexed for MEDLINE]Related articles

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.

Pieber TR, Draeger E, Kristensen A, Grill V.

Diabet Med. 2005 Jul;22(7):850-7.PMID: 15975098 [PubMed - indexed for MEDLINE]Related articles

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

Bartley PC, Bogoev M, Larsen J, Philotheou A.

Diabet Med. 2008 Apr;25(4):442-9.PMID: 18387078 [PubMed - indexed for MEDLINE]Related articlesFree article

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.

Diabet Med. 2007 Jan;24(1):27-34.PMID: 17227321 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.

De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.

Diabetes Obes Metab. 2005 Jan;7(1):73-82.PMID: 15642078 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR.

Diabet Med. 2006 Jul;23(7):729-35.PMID: 16842476 [PubMed - indexed for MEDLINE]Related articles

Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.

Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB.

Diabetes Care. 2003 Mar;26(3):799-804.PMID: 12610040 [PubMed - indexed for MEDLINE]Related articlesFree article

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.

Vasc Health Risk Manag. 2009;5(1):121-8. Epub 2009 Apr 8.PMID: 19436668 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group.

Clin Ther. 2004 Apr;26(4):502-10.PMID: 15189747 [PubMed - indexed for MEDLINE]Related articles

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.

Davies MJ, Derezinski T, Pedersen CB, Clauson P.

Diabetes Technol Ther. 2008 Aug;10(4):273-7.PMID: 18715200 [PubMed - indexed for MEDLINE]Related articles

Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?

Valensi P, Cosson E.

Diabetes Metab. 2005 Sep;31(4 Pt 2):4S34-4S39. Review.PMID: 16389896 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.

Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S; PREDICTIVE Study Group.

Curr Med Res Opin. 2008 Feb;24(2):369-76.PMID: 18096110 [PubMed - indexed for MEDLINE]Related articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles